INBP (Integrated Biopharma) Moat Score: 2/10 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBP Integrated Biopharma Inc INBP
36 GF Score
Price $0.16
GF Value $0.26
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Integrated Biopharma Moat Score?

Integrated Biopharma INBP 36 Moat Score is 2 as of Jul. 31, 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 2,052 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 88.6% on this metric.

Integrated Biopharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Integrated Biopharma has No Moat: Integrated Biopharma Inc operates in the nutraceuticals industry with low barriers to entry and limited proprietary technology. It lacks significant market share, brand strength, or regulatory advantages to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Integrated Biopharma might have No Moat - Very weak/transient advantages.

Integrated Biopharma  (OTCPK:INBP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Integrated Biopharma Moat Score Related Terms

INBP vs HCWC, PAVS, BABB: Moat Score Comparison

For the Packaged Foods subindustry, Integrated Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Biopharma Moat Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Moat Score falls into.


INBP
36GF Score
Integrated Biopharma Inc INBP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Integrated Biopharma (INBP) has a Moat Score of 2 as of Jul. 31, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Integrated Biopharma ranks #234 out of 2052 companies in the Consumer Packaged Goods industry, placing it in the top 11.4%.
Is Integrated Biopharma's Moat Score too high?
Integrated Biopharma's current Moat Score is 2. Based on the distribution chart, Integrated Biopharma ranks #234 out of 2052 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Moat Score compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #234 out of 2052 companies for Moat Score. This places Integrated Biopharma in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Consumer Packaged Goods company?
A good Moat Score depends on the Consumer Packaged Goods industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Integrated Biopharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current Moat Score is 2. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Moat Score is 2 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Biopharma (INBP) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued. The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26. GuruFocus considers Integrated Biopharma to be Possible Value Trap.

Key valuation signals for INBP:

  • Moat Score: 2
  • GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrated Biopharma Business Description

Address 225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score

Get the complete analysis for INBP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price
$0.26
GF Value